James - Slack Capital

From The @villagevoice: The Metabolic Engine - How Scientists Are Exploring a New Path Beyond GLP-1 Weight-Loss Drugs America’s weight-loss conversation has changed almost overnight. Prescription drugs once reserved for diabetes treatment are now household names, promising dramatic results on the scale. Many therapies currently available focus on reducing appetite or limiting calorie intake, which can certainly lead to weight loss. Yet those solutions often address the symptom rather than the deeper metabolic engine driving the condition. Interest is growing around strategies that target the body’s internal energy system itself. Instead of simply telling the body to eat less, researchers are investigating ways to improve how the body burns energy, processes fat, and maintains metabolic balance. That shift in thinking has opened the door to a small but intriguing molecule known as N-trans-Caffeoyltyramine, or NCT. Full story available here: na2.hubs.ly/H04N4_c0

We're featured in this brilliant National Lab of the Rockies (formerly NREL) piece on cell-free biomanufacturing: “Cell-free biocatalysis for biomanufacturing - or cell-free biomanufacturing - essentially operates enzymatic cascades without the constraints of a living cell. This is a technology that could transform the bioenergy sector but also pharma and fine chemicals,” explained Yannick Bomble, an NLR principal scientist and an R&D leader in cell-free biomanufacturing. Full story from @NatLabRockies available here: na2.hubs.ly/H04FbxG0 #exozymes #biomanufacturing #exozyme #NREL #NLR $EXOZ

CCO at @eXoZymes, Damien Perriman, interviewed at @Nasdaq around our NCT project: "We’ve shown that we can go from idea to 100× pilot scale in 12 months - and hit it right the first time. That kind of speed and predictability is exactly what this industry has been missing, and it’s what turns a single success into a repeatable value engine." #exozymes #exozyme #enzymes #enzyme #NCT #Nasdaq #ntranscaffeoyltyramine $EXOZ